Study of Tocilizumab to Treat Polymyalgia Rheumatica

Summary

This is a fifteen-month open label, Phase IIa clinical trial is being conducted to assess the tolerability, safety and efficacy of a medication called Tocilizumab (Actemra®) in patients with polymyalgia rheumatica (PMR).

Timeline

Start

2011-04

Primary completion

2015-12

Completion

2016-01

Drugs

Indications